Bank of Nova Scotia
XLRN

Bank of Nova Scotia’s Acceleron Pharma XLRN Stock Holding History

Bank of Nova Scotia’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,958
Closed -$497K – 1226
2021
Q2 		$497K Buy
+3,958
New +$499K ﹤0.01% 983

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Bank of Nova Scotia's XLRN Position: Q3 2021 in Review

Bank of Nova Scotia sold out of Acceleron Pharma (XLRN) in Q3 2021, closing a stake of 3,958 shares — an estimated $497K sold.

Bank of Nova Scotia first reported a position in XLRN in Q2 2021 and held it in 1 quarter. The position peaked at $497K in Q2 2021. 330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

  • Bank of Nova Scotia reported no remaining Acceleron Pharma position as of Q3 2021 after selling out during the quarter.
  • Bank of Nova Scotia sold 3,958 Acceleron Pharma shares in Q3 2021, an estimated $497K.
  • Bank of Nova Scotia first reported a position in Acceleron Pharma in Q2 2021 and held it in 1 quarter.
  • Bank of Nova Scotia's Acceleron Pharma position peaked at $497K in Q2 2021.
  • 330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Bank of Nova Scotia's 13F filing for Q3 2021, filed 12 Nov 2021.